Status:
UNKNOWN
Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform
Lead Sponsor:
The Second Affiliated Hospital of Chongqing Medical University
Collaborating Sponsors:
Cellomics International Limited
Conditions:
Hepatocellular Carcinoma
Circulating Tumor Cell
Eligibility:
All Genders
18-70 years
Brief Summary
This study aims to isolate CTCs in peripheral venous blood of liver cancer patients by inertial focusing principle-based microfluidic device, determine the relationship between the number of CTCs and ...
Detailed Description
In China, the incidence of hepatocellular carcinoma (HCC) ranks the fourth, and the mortality rate is the second. Less than 20% of the patients were able to receive curative resection therapy. Most ot...
Eligibility Criteria
Inclusion
- confirmed by imaging and serological examination for benign liver cancer;
- patients without any previous treatment;
- informed consent;
- age: 18 years or older (adult).
Exclusion
- with other malignancies;
- metastatic liver tumors;
- with major organic lesions;
- with acute complications such as acute liver failure, massive gastrointestinal bleeding and so on.
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05242237
Start Date
December 1 2021
End Date
January 31 2024
Last Update
February 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the second affiliated hospital of Chongqing Medical University
Chongqing, China